ERBB2 and breast carcinoma: Recent evidence showed that TILs have been observed in HER2-positive breast cancer and TNBC patients, and TNBC cases marked by significant lymphocyte infiltration demonstrated enhanced long-term survival rates and a superior response to chemotherapy [64].